Brigatinib
ROS1 Gene Mutation
Sameek RoychowdhurySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the ROS1 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin University of Southern California | Phase 2 | B |
Carboplatin Centre Francois Baclesse | Phase 2 | B |
Pembrolizumab University of Southern California | Phase 2 | B |
Atezolizumab Centre Francois Baclesse | Phase 2 | B |
Cyclophosphamide University of Southern California | Phase 2 | B |
View all 14 →
Same molecule, other indications
Brigatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →